If a treatment can damage cancer cells in a dish, does that mean it helps people with cancer? The tempting answer is yes: identify a physical mechanism, then expect the predicted benefit. But a mechanism explains how an effect could happen; it cannot by itself show how often it happens in patients, whether harms offset it, or whether the treatment improves outcomes that matter.
A mechanism is a route, not a destination
A mechanism is a chain of cause and effect. Imagine a therapy that delivers energy to a tumor. The energy might alter molecules, damage cells, and eventually slow their division. Each link can be scientifically plausible and still leave open whether enough tumor cells are affected in a person to change the illness.
The body adds obstacles that a dish of cells does not contain. Energy may spread unevenly; healthy tissue may also respond; the tumor may differ from the cells tested; and the patient’s immune system and other treatments may change the result. A mechanism narrows the possibilities worth testing. It does not supply the missing patient outcome.
From cell response to clinical question
Consider cold atmospheric plasma, a gas containing electrically energized particles and reactive chemical species. In laboratory settings, such ingredients can damage cancer cells. That gives researchers a reason to investigate the approach, but cell death under controlled conditions is not the same endpoint as longer survival, symptom relief, or fewer recurrences in people.
A phase I study of a cold-plasma device treated 20 people with advanced or recurrent solid tumors during surgery. Its primary purpose was safety, alongside the operation; its secondary measures included recurrence and survival. The authors reported no related adverse events in that group, but a small early-phase study cannot establish that the plasma caused cancer control or that the approach works broadly [2]. [3]
What trials add
Clinical trials are research studies designed to test how well medical approaches work in people. Different studies ask different questions: treatment trials evaluate ways to treat cancer, while supportive-care trials examine ways to improve quality of life or manage treatment effects [1]. A result is meaningful only in relation to the question, participants, comparison, and outcome the study was designed to assess.
To estimate a treatment’s effect, researchers need a comparison that helps distinguish the intervention from other causes of change. Tumors can change over time; surgery, existing therapies, and patient characteristics can all matter. A carefully designed comparison helps separate those influences. Larger studies may then test whether an early signal persists and whether benefits outweigh harms in a broader group.
Read the claim at the right scale
When you encounter a treatment claim, ask what was actually measured. Was it a change in cells, a short-term safety outcome, tumor response, symptom burden, or survival? These are not interchangeable. A study can answer one question well while leaving the others open. The stage of research also matters: an early trial is a step toward knowledge, not a final verdict.
The useful mental experiment is to imagine two patients with the same tumor. One receives a new intervention and one does not, while everything else stays equal. In real research, perfect matching is difficult, so trial design tries to make the comparison fair and account for uncertainty. A convincing mechanism helps explain a result after it appears; the test in people determines whether the expected benefit is actually observed.
Sources & further reading
- Clinical Trials: What Are the Phases? National Cancer Institute
- First Cold Atmospheric Plasma Phase I Trial for Advanced Solid Tumors Canady et al., Cancers (2023)
- Learn About Clinical Trials National Eye Institute
Prepared for the independent PSI Center reading library. About edition dates and source checking.
This explainer describes scientific principles. It does not assess individual treatment choices.
